Morales-Hernández AE, Valdez- Rojas L, Hernández-Salcedo DR

Language: Spanish
References: 21
Page: 129-145
PDF size: 663.69 Kb.

ABSTRACT

Monoclonal gammopathy is a heterogeneous group of disorders characterized by the proliferation of plasma cells producing immunoglobulins equal to each other, which are called monoclonal immunoglobulins or M component. Within the group of monoclonal gammopathy, monoclonal gammopathy of undetermined significance is the most common and is defined by the presence of component monoclonal IgG, IgA or IgM in serum. About 10% of patients with peripheral neuropathy monoclonal gammopathy, which may be related to a monoclonal antibody with reactivity to myelin associated glycoprotein. Peripheral neuropathy is the only clinically significant neurological complication of monoclonal gammopathy of undetermined significance. We present the case report of a male 63-year-old with an affection of a month of evolution, characterized by pain in the lateral aspect of the right ankle, accompanied by numbness in the whole limb. The routine tests showed slight elevation of total serum globulin proteins at the expense; additional tests were performed, which reported increased free kappa and lambda light chains and gammaglobulin, which agreed with monoclonal gammopathy. The study of the patient was completed by electrophysiological studies and bone marrow aspirate, which indicated the same diagnostic hypothesis. In the study of patients with symptoms of neuropathy, we should include metabolic, degenerative, secondary hypothesis overweight and obesity, anatomical malformations and, in this case, secondary to proliferation of plasma cells. The recognition of the underlying plasma cell disorder is of great importance, as it requires a proper diagnosis, monitoring and treatment provided when indicated.

REFERENCES

1. De Rivas Otero B, Álvarez Álvarez B. Gammapatía monoclonal de significado incierto. A propósito de un caso. 2006;32.

2. Kyle RA, Therneau TM. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-1369.

3. Presto DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 1994;137:68-97.

4. Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009;27:4585-4590.

5. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-1757.

6. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 2000;96:808-822.

7. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-2221.

8. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-1558.

9. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002;100:1417-1424.

10. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001;20:5611-5622.

11. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569-4575.

12. Magrangeas F, Lodé L, Wuilleme S, et al. Genetic heterogeneity in multiple myeloma. Leukemia 2005;19:191-194.

13. Jego G, Bataille R, Geffroy-Luseau A, et al. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006;20:1130-1137.

14. Mantovani A, Garlanda C. Inflammation and multiple myeloma: the Toll connection. Leukemia 2006; 20:937-938.

15. Bohnhorst J, Rasmussen T, Moen SH, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006;20:1138-1144.

16. Mariel Emilce Alejandre, Federico Sackmann, et al. Gammapatía monoclonal de significado incierto: factores de pronóstico, evolución y riesgo. Acta Bioquim Clin Latinoam 2013;47:71-84.

17. Bories C, Jagannath S. Asymptomatic monoclonal gammopathies. Clin Lymphoma, Myeloma Leuk 2014;14:78-86.

18. Decaux O, et al. Systemic manifestations of monoclonal gammopathy. Eur J Intern Med 2009;20:457-461.

19. Bladé J. Clinical practice. Monoclonal gammopathy of undetermined significance. N Engl J Med 2006;355;2765-2770.

20. Rajkumar SV, Lacy MQ. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev 2007;21:255-265.

21. Sobol U. Neurologic aspects of plasma cell disorders. Handb Clin Neurol 2014;120:1083-1099.